The relationship between obesity and type 2 diabetes has been known for decades and the recent important increase in such diseases represents a major medical problem worldwide. Several prospective studies present both impaired insulin release and insulin resistance as the major factors for the development of type 2 diabetes. The factor that dominates in obesity is the permanent elevation of plasma FFA and the predominant utilization of lipids by the muscle inducing a diminution of glucose uptake and, therefore, insulin resistance. The rise in insulin secretion appears to be a compensatory mechanism that responds to the increased levels of circulating glucose. The fall in insulin secretion occurs as a late phenomenon. The present review aims at analysing the mechanisms that lead human obesity to type 2 diabetes and using the pathophysiological information for the prevention of diabetes. The partial reversibility of the evolution of obesity towards diabetes is well demonstrated today by lifestyle changes and multidisciplinary weight loss programs.
Introduction
The relationship between obesity and type 2 diabetes has been known for years and it is estimated that about 60 -90% of all patients with type 2 diabetes are or have been obese. 1 The reverse, however, is not true and the majority of obese patients do not become diabetic. Obesity has to be considered as only one of the factors that lead to diabetes. In the obesity -diabetes relationship, two factors are recognized to be the major components: insulin resistance and insulin deficiency. These two factors are closely related in a dual regulatory cycle in which hyperglycemia stimulates insulin secretion which, in turn, lowers the rise in glycemia. 2 The effect of glucose is produced by generating triggering and amplifying signals in the beta-cells. 3 Chronic hyperglycemia, by means of the glucotoxicity phenomenon, impairs insulin sensitivity, 4 while sustained hyperinsulinemia inhibits both insulin secretion 5 and insulin action. 6 Both insulin resistance and insulin deficiency may present genetic implications in the development of the diabetes of the obese. 7 This review will discuss the relationships between obesity and diabetes, between insulin resistance and the possibility of deficiency of insulin secretion, as well as the pathophysiology of obesity-related diabetes.
Insulin deficiency -insulin resistance relationship
Several prospective studies 8, 9 have presented both impaired insulin release and insulin resistance as the major factors for the development of type 2 diabetes. In a study on 200 nondiabetic Pima Indians, 8 diabetes developed in 38 subjects during a 5.3 y follow-up. Insulin resistance was shown to be a major risk factor for the development of type 2 diabetes, while a low acute insulin response to glucose was considered as an additional but weaker risk factor and hepatic overproduction of glucose did not predict the occurrence of diabetes. The degree of obesity had little or no effect in predicting diabetes.
The double existence of insulin resistance and decreased capacity for insulin secretion in the development of type 2 diabetes in obese subjects is confirmed by the study of Haffner et al 9 on Mexican-Americans. The authors showed that decreased insulin secretion and increased insulin resistance are independently related risks in their 7 y study. Abnormal insulin secretion, as assessed by the ratio of the change in insulin to change in glucose from 0 to 30 min on an oral glucose tolerance test (DI 30 =DG 30 ) in insulin-resistant obese subjects, was shown to predict the development of type 2 diabetes in obese subjects with normal glucose tolerance. The incidence of over 7 y was 33% in the subjects with low 'insulin secretion' (DI 30 =DG 30 ) and high fasting insulin used as an index of 'insulin resistance', compared with 2.4% for subjects with high (DI 30 =DG 30 ) and low fasting insulin.
The two studies do not, however, address the issue of which of impaired insulin release and insulin resistance precedes the other. For Gerich, 7 impaired insulin secretion would be the initial and main factor predisposing to type 2 diabetes. Based on studies 10, 11 demonstrating that individuals with impaired glucose tolerance already have impaired insulin secretion, the author shows a progressive decrease in the early plasma insulin response as glucose tolerance deteriorates. There is evidence that impaired pancreatic beta cell function would precede the onset of glucose intolerance. This view is not in full opposition with the study on obesity duration reported previously, 12 -14 which shows obesity as an important cause of insulin resistance that stimulates insulin secretion as a compensatory mechanism. Diabetes occurs when the capacity for insulin secretion is overcome and fails to oppose the resistance to decreased glucose uptake. 15 Genetic and environmental origin of diabetes in obesity Diabetes of the obese has strong genetic and environmental components. 7, 16, 17 Obesity has a polygenic mode of inheritance. Ethnological studies have shown a genetic origin for the susceptibility of obesity, but the major factor remains environmental. 18 Obesity or tendency to obesity might have a genetic origin, but its genes have to be considered as risk factors, whereas genes affecting insulin secretion may be the primary genetic factors and, according to Gerich, impaired insulin secretion would be the initial and main genetic factor predisposing to type 2 diabetes. 7 Differing from insulin resistance, which is generally reversible, the decrease in insulin secretion was never shown to be restored to normal. Insulin resistance, a mainly acquired problem, remains of capital importance in the pathogenesis of type 2 diabetes in the obese. As proposed by Zimmet, the lifestyle-related type 2 diabetes rises from the 'collision of our old 'hunter-gatherer' genes with our new twentieth-century way of life'. 18 Obesity and insulin resistance Obesity is a major factor of insulin resistance. Insulin resistance is apparent already early in the development of obesity, long before any occurrence of diabetes, seen through the elevated plasma glucose levels both in the basal state and in response to hyperglycemia in the course of an oral glucose tolerance test (OGTT; Figure 1 ). The rise of insulin represents a compensatory mechanism for maintaining glycemia within normal limits. Insulin resistance can be demonstrated by the lowering of nonoxidative glucose disposal in the course of a euglycemic, hyperinsulinemic clamp ( Figure 2 ). The conditions of the clamp, by preventing the physiological rise in glycemia and insulinemia which normally compensates for the limitations in glucose uptake, demonstrate insulin resistance in the early state of obesity before impairment of glucose tolerance. In the physiological situation, during OGTT, when plasma insulin and glucose are free to rise, nonoxidative glucose disposal is remaining within normal rates in the nondiabetic patients. It falls with the occurrence of diabetes.
Obesity and plasma FFA
The factor that dominates in obesity is the permanent elevation of plasma free fatty acids (FFA), both in the basal state and following a glucose load, where the fall remains limited. 19, 20 Elevated plasma FFA levels represent a major factor at the origin of insulin resistance in obesity. Fat distribution influences insulin resistance with increased release of FFA Figure 1 Plasma glucose and insulin concentration in the course of a 3 h oral glucose tolerance test in four groups of obese patients and lean control subjects, young (left) and older (right). Data from Felber et al. 28 Figure 2 Glucose storage rate in nondiabetic and diabetic obese subjects during 100 g oral glucose tolerance test (above) and euglycemic clamp (below). Data from Felber et al. From obesity to diabetes J-P Felber and A Golay from visceral fat cells to the portal venous system. 21 In experimental conditions, the rise of plasma FFA by means of a triglyceride emulsion infused during the 2 h preceding an OGTT in a group of normal subjects was shown to induce impaired glucose tolerance with an increased rise of both plasma glucose and insulin ( Figure 3) . Conversely, impaired glucose tolerance and the elevated insulin response in a group of nondiabetic obese patients was normalized following a 2 h infusion of a FFA-lowering precursor of nicotinic acid. 22 In another study, insulin resistance was demonstrated by the fall in nonoxidative glucose disposal in the course of a euglycemic, hyperinsulinemic clamp following the rise of plasma FFA induced by a 2 h infusion of a triglyceride emulsion. 23 Insulin resistance was shown to largely result from decreased rates of glycogen synthesis in skeletal muscle. 24 A study using magnetic resonance spectroscopy and a euglycemic, hyperinsulinemic clamp following a 5 h infusion of intralipid and heparin showed that plasma FFA induce insulin resistance through inhibition of glucose transport activity. 25 The same mechanism was previously proposed by the same group in obese patients, using slightly different experimental conditions. 26 The predominant utilization of lipids at the expense of glucose by muscle, as shown by the increase in lipid oxidation, might also contribute to the decrease of glucose uptake and, therefore, to insulin resistance. 27, 28 The resulting decrease in glycogen mobilization might be at the origin of a retrograde inhibition of glycogen synthase activity, another possible cause of decreased glucose uptake and, therefore, of insulin resistance. 14 
Studies on obesity duration
The duration of obesity has been shown to be an important risk factor for type 2 diabetes. It exerts its own effects, distinct and independent of age. 29 Prospective studies have shown the importance of obesity at the origin of glucose intolerance and type 2 diabetes. 12 -14,30 -37 Progression of obesity toward diabetes has been studied by cross-sectional and sequential studies. A cross-sectional study, in which 67 obese patients took part, showed the progression of glucose intolerance and the occurrence of diabetes during 50 y of obesity duration. 12, 13 Contrasting with the constant elevation of both basal and total plasma FFA and of lipid oxidation measured by indirect calorimetry in the course of a 3 h OGTT (Figure 4) , changes in glycemia and insulinemia were observed through the years of obesity duration. During the first 10 -20 y, basal plasma glycemia was remaining within normal levels, before rising in the following years. Plasma insulin was remaining only slightly elevated during the first 10 y, an early sign of insulin resistance, before rising to high levels in the subsequent years. The insulin response to the glucose load became very high during the first 10 -20 y before falling thereafter. This showed the existence of a compensated state during the first 10 -20 y of obesity duration.
In that study, basal glycemia and nonoxidative glucose disposal were closely related, confirming the dependence of glycemia on glucose uptake. Glycemia and nonoxidative glucose uptake remained normal during the first 17 y of obesity duration ( Figure 5 ). In that prediabetic state, the glycemic response to the glucose load was impaired, accompanied by an important insulin response. This insulin rise in response to increasing glycemia limiting increases of plasma glucose concentrations could apparently maintain glucose uptake within its normal limits.
The occurrence of diabetes after variable periods of obesity duration was shown by the simultaneous rise in basal glycemia and fall in nonoxidative glucose disposal during the OGTT ( Figure 5 ). These two variables were negatively correlated (P < 0.001), an indication for the effect of the decreased glucose uptake on the rise in basal glycemia. The marked rise of plasma insulin in response to the glucose load was replaced by an almost total fall of insulin with the occurrence of diabetes (Figure 4) . It confirms the importance of the decrease in insulin secretion in the occurrence of diabetes in obesity. The causes of this decline in insulin secretory response are unknown. It might perhaps be explained by the effect of glucotoxicity causing desensitization of insulin secretion, a consequence of prolonged hyperglycemia. 4 Another explanation would be lipotoxicity, ie the loss of insulin secretion secondary to the accumulation of triglycerides in the pancreatic islets, a consequence of the increase in circulating plasma FFA. 38 Mention should be made of the intermediary and transitory period that precedes the fall of insulin. In the beginning, diabetes is accompanied by a high insulin response to Figure 4 Basal and total lipid oxidation, fasting plasma glucose, increase over basal glucose level (D glucose), basal plasma insulin levels and increase over basal insulin levels in response to the glucose tolerance test in function of obesity duration (from Felber et al 13 ).
From obesity to diabetes J-P Felber and A Golay the glucose load of the OGTT, the hyperinsulinemic phase of diabetes in obesity (Figure 1 ). The high insulin response generally lasts for a few years, before falling to low levels. 12 -14 It shows that the very high insulin levels do not permit any more to compensate for the defect in glucose uptake and suggests that insulin resistance might precede total insulin deficiency.
This cross-sectional study was confirmed, in part, by a prospective one where 33 obese patients were restudied after 6 y, using the same metabolic measurements. 39 It showed evolution of obesity toward diabetes through the rise in glycemia and impairment of nonoxidative glucose disposal during a 3 h OGTT (Figure 6 ). In the course of the 6 y of observations, some of the obese glucose tolerant patients became diabetic. It also showed that the previously hyperinsulinemic obese diabetic patients lost their hyperinsulinemia for a lack of insulin response to the glucose load, confirming the transient state of obese hyperinsulinemic diabetes. Similarly, the recent study of De Vegt et al reported a 64.5% progression to diabetes of patients with both impaired fasting glucose and impaired glucose tolerance during a 6 y follow-up compared with 4.5% for those with normal glucose levels at baseline. 40 The dependence of the evolution of obesity toward diabetes from insulin resistance is also demonstrated by its partial reversal after dietary treatment. Weight loss of more than 10 kg body weight in a group of 26 obese patients was followed by the marked improvement of nonoxidative glucose disposal in relation to the lowering of the increment in glycemia in response to the glucose load 40 ( Figure 7 ). This study confirms once more the close relationship between Figure 5 Relationship between the individual values of (a) fasting glucose concentration and (b) glucose storage measured as nonoxidative glucose disposal during a 100 g oral glucose tolerance test (from Felber 12 ).
Figure 6
Evolution of glucose storage measured as nonoxidative glucose disposal and D glucose (increment over basal levels) during a 100 g oral glucose tolerance test between the first and the second test in a 6 y follow-up of obese subjects presenting with normal glucose tolerance, impaired glucose tolerance, and hyperinsulinemic diabetes (from Jallut et al 39 ).
Figure 7
Evolution of glucose storage measured as nonoxidative glucose disposal and D glucose (increment over basal levels) during a 100 g oral glucose tolerance test between the first and the second test after weight loss (>10 kg) in obese subjects presenting with normal glucose tolerance, impaired glucose tolerance, and hyperinsulinemic and hypoinsulinemic diabetes. Data from Golay et al. 41 obesity and insulin resistance. Similar observations were reported by others. 41 -44 The above studies show the important role of insulin resistance in obesity through the progressive decrease in the capacity of tissues to take-up glucose. The rise in insulin secretion appears to be a compensatory mechanism that responds to the increased levels of circulating glucose. The fall in insulin secretion occurs as a late phenomenon.
Pathophysiological bases of prevention of diabetes in obesity and therapy
Prevention of the development of diabetes in obesity and therapy are based on the pathophysiology of this evolution. It is acting on the two major factors involved: insulin resistance and decreased insulin secretion.
Insulin resistance is characterized, in obese patients, by the permanently elevated plasma FFA. Prevention and therapy therefore need to tend to decrease plasma FFA by acting on obesity through weight loss. It is also important to reduce fat intake as the large mass of adipose tissue, in human obesity, results mainly from excessive deposition of ingested lipids, whereas the conversion of ingested carbohydrates into lipids is a minor metabolic pathway in man. 42, 43 Due to its reversibility, the decrease of insulin resistance represents an interesting and valuable goal.
The other point of impact is the action on insulin secretion. This factor is also of great importance but usually not totally reversible. Stimulation of insulin secretion is often used in therapy. It should, however, be taken into consideration that insulin is basically a hormone favoring storage of both glucose as glycogen and fatty acids as triglycerides. The stimulation of fat deposition into the fat stores does not help in obese patients. The recent discovery of the effect of the new group of glitazones in reducing the triglyceride content of the b-cells, improving insulin secretion in response to glucose and preventing the death of beta-cells, is of great interest in the prevention of the occurrence of diabetes in rats. 46 Prevention of the loss of b-cell function through lipoaptosis by treatment with troglitazone, as shown in the rat, has not yet been reported in clinical studies. 47 It might be of interest in the future. In humans, the glitazones not only diminish lipid oxidation and improve insulin resistance but also increase body fat storage.
On the basis of studies that demonstrate partial reversibility of the evolution of obesity toward diabetes, 41 -45 great efforts were carried out on the prevention of diabetes in obese patients. 48 -50 Lifestyle changes related to obesity, eating behavior and physical activity were proposed to obese patients. The Finnish diabetes preventing study group 50 reported important reduction of the risk of diabetes, which was reduced by 58% (P < 0.001) in a group of 522 overweight subjects. The obese subjects, with a mean age of 55 y, were studied for a period of 3.2 y. They received individualized counseling aimed at reducing weight, total intake of fat and of saturated fat, and increased intake of fibers. Physical activity was also an important part of the program, as physical inactivity is known to be one of the main nongenetic determinants of insulin resistance. The studies reported by others all report beneficial effects of dietary treatment, generally combined with increase in physical activity.
Conclusions
The recent important increase in both obesity and type 2 diabetes and their close relationship represent presently a major medical problem in large parts of the world. 51 While the decrease of insulin secretion, with its genetic components, is of importance, the environmental factors that lead to obesity appear to be largely responsible for the growing increase of diabetes. 52 The present review has tried to analyze and to understand the mechanisms that lead human obesity to type 2 diabetes and to use the pathophysiological information for the prevention of diabetes in obese subjects.
